Which could be the next steps? First of all, the approval of the P-tau217 A-beta42 ratio may be the first step for the inclusion of these plasma biomarkers in the diagnostic process. So what’s next? Maybe I think that an important point, an important question to address is what about those patients with intermediate levels of plasma biomarkers? So can we develop other plasma biomarkers that could help us for the interpretation of those patients in the gray zone, so with an intermediate risk, before doing or performing CSF or amyloid PET? This is the first question...
Which could be the next steps? First of all, the approval of the P-tau217 A-beta42 ratio may be the first step for the inclusion of these plasma biomarkers in the diagnostic process. So what’s next? Maybe I think that an important point, an important question to address is what about those patients with intermediate levels of plasma biomarkers? So can we develop other plasma biomarkers that could help us for the interpretation of those patients in the gray zone, so with an intermediate risk, before doing or performing CSF or amyloid PET? This is the first question. The second question is, specific plasma biomarkers of AD pathology are proposed to be used as diagnostic biomarkers, so for diagnostic purposes. But maybe we can develop specific fluid biomarkers also for the staging of Alzheimer’s disease. And this could be very helpful in order to avoid more expensive exams, for example, the tau PET in the future. And it could be interesting considering the future venue of disease-modifying treatments.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
